Enrichment of vascular endothelial growth factor secreting mesenchymal stromal cells enhances therapeutic angiogenesis in a mouse model of hind limb ischemia

Park, Jin Sil; Bae, Seong Ho; Jung, Subin; Lee, Minhyung; Choi, Donghoon

doi:10.1016/j.jcyt.2018.12.007

Cited by 14 publications

(11 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This review reports the treatment of lungs, heart, kidneys and liver by the injection of MSC or the MSC’s secretome. Others organs were treated with success such as the brain [107], the intestines [108], the limbs [109], the retina [110] and the spinal cords [111] to prevent IRI in animal models. Most of the studies were conducted on small and large animals with a positive outcome.…”

Section: Discussion and Perspectivesmentioning

confidence: 99%

Therapeutic Properties of Mesenchymal Stem Cell on Organ Ischemia-Reperfusion Injury

Oliva¹

2019

IJMS

View full text Add to dashboard Cite

The shortage of donor organs is a major global concern. Organ failure requires the transplantation of functional organs. Donor’s organs are preserved for variable periods of warm and cold ischemia time, which requires placing them into a preservation device. Ischemia and reperfusion damage the organs, due to the lack of oxygen during the ischemia step, as well as the oxidative stress during the reperfusion step. Different methodologies are developed to prevent or to diminish the level of injuries. Preservation solutions were first developed to maximize cold static preservation, which includes the addition of several chemical compounds. The next chapter of organ preservation comes with the perfusion machine, where mechanical devices provide continuous flow and oxygenation ex vivo to the organs being preserved. In the addition of inhibitors of mitogen-activated protein kinase and inhibitors of the proteasome, mesenchymal stem cells began being used 13 years ago to prevent or diminish the organ’s injuries. Mesenchymal stem cells (e.g., bone marrow stem cells, adipose derived stem cells and umbilical cord stem cells) have proven to be powerful tools in repairing damaged organs. This review will focus upon the use of some bone marrow stem cells, adipose-derived stem cells and umbilical cord stem cells on preventing or decreasing the injuries due to ischemia-reperfusion.

show abstract

Section: Discussion and Perspectivesmentioning

confidence: 99%

Therapeutic Properties of Mesenchymal Stem Cell on Organ Ischemia-Reperfusion Injury

Oliva¹

2019

IJMS

View full text Add to dashboard Cite

show abstract

“…In addition to conducting studies about stem cell transplants, researchers have also combined growth factors with stem cells to explore their effects on angiogenesis. Park et al (2019) used VEGF and…”

Section: Stem Cell Therapymentioning

confidence: 99%

Advances for the treatment of lower extremity arterial disease associated with diabetes mellitus

Yang

Luo

Hong

et al. 2022

Front. Mol. Biosci.

View full text Add to dashboard Cite

Lower extremity arterial disease (LEAD) is a major vascular complication of diabetes. Vascular endothelial cells dysfunction can exacerbate local ischemia, leading to a significant increase in amputation, disability, and even mortality in patients with diabetes combined with LEAD. Therefore, it is of great clinical importance to explore proper and effective treatments. Conventional treatments of diabetic LEAD include lifestyle management, medication, open surgery, endovascular treatment, and amputation. As interdisciplinary research emerges, regenerative medicine strategies have provided new insights to treat chronic limb threatening ischemia (CLTI). Therapeutic angiogenesis strategies, such as delivering growth factors, stem cells, drugs to ischemic tissues, have also been proposed to treat LEAD by fundamentally stimulating multidimensional vascular regeneration. Recent years have seen the rapid growth of tissue engineering technology; tissue-engineered biomaterials have been used to study the treatment of LEAD, such as encapsulation of growth factors and drugs in hydrogel to facilitate the restoration of blood perfusion in ischemic tissues of animals. The primary purpose of this review is to introduce treatments and novel biomaterials development in LEAD. Firstly, the pathogenesis of LEAD is briefly described. Secondly, conventional therapies and therapeutic angiogenesis strategies of LEAD are discussed. Finally, recent research advances and future perspectives on biomaterials in LEAD are proposed.

show abstract

“…One such attempt by Park et al, transduced MSC via plasmid transduction to overexpress Green Fluorescent Protein (eGFP) and Vascular Endothelial Growth Factor (VEGF), they then utilized Fluorescent Activated Cell Sorting (FACS) analysis to ensure only cells expressing the target gene were included in the treatment. These were then transplanted into a hindlimb ischemia model where they demonstrated improved limb reperfusion, and muscle repair effects, when compared with control MSC [ 45 ]. Another approach, either via a Transcription Activator-Like Effector Nucleases (TALEN) [ 46 ] or lentiviral transduction [ 47 ], increased expression of dual chemotactic genes, granulocyte chemotactic protein-2 (GCP-2) and stromal-derived factor-1 (SDF-1α).…”

Section: Increasing Cell’s Therapeutic Potentialmentioning

confidence: 99%

Increasing The Therapeutic Potential Of Stem Cell Therapies For Critical Limb Ischemia

Velázquez¹

2020

SRDT

View full text Add to dashboard Cite

Peripheral Arterial Disease (PAD) is a progressive, atherosclerotic disease that at its end stage, Critical Limb Ischemia (CLI), results in severely diminished limb perfusion and causes leg pain at rest, non-healing ulcers, and tissue gangrene. Many patients with CLI fail current medical and surgical therapies and thus are deemed “no option” and require limb amputation. Novel therapies to attempt limb salvage in these “no option” patients are needed. Stem cell therapy is one therapeutic angiogenic avenue that has been tested over the last 20 years. To date, clinical trials have shown promise but with only modest improvement and none demonstrated a significant decrease in amputation rates in those treated with stem cell therapy. Thus, recent investigations into improving stem cell therapy have been the focus of our laboratory and many others. This review aims to describe recent advances in increasing the therapeutic potential of stem cell therapies for CLI.

show abstract

Enrichment of vascular endothelial growth factor secreting mesenchymal stromal cells enhances therapeutic angiogenesis in a mouse model of hind limb ischemia

Cited by 14 publications

References 46 publications

Therapeutic Properties of Mesenchymal Stem Cell on Organ Ischemia-Reperfusion Injury

Therapeutic Properties of Mesenchymal Stem Cell on Organ Ischemia-Reperfusion Injury

Advances for the treatment of lower extremity arterial disease associated with diabetes mellitus

Increasing The Therapeutic Potential Of Stem Cell Therapies For Critical Limb Ischemia

Contact Info

Product

Resources

About